Crescent Biopharma Inc. has released a corporate presentation detailing its advancements in oncology therapies. The company is focusing on developing a pipeline of potentially best-in-class therapies for the treatment of solid tumors. Crescent Biopharma is advancing three oncology programs, including CR-001, a PD-1 x VEGF cooperative tetravalent bispecific antibody, and two ADCs, CR-002 and CR-003, with topoisomerase inhibitor payloads. The presentation also highlights Crescent's strategy to reproduce ivonescimab's pharmacology and its potential to penetrate the PD-$(L)$1 immunotherapy market. You can access the full presentation through the link below.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Crescent Biopharma Inc. published the original content used to generate this news brief on September 04, 2025, and is solely responsible for the information contained therein.